Skip main navigation
Close Drawer MenuOpen Drawer Menu

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
Disclosure of Editors' Financial RelationshipsFull Access

Disclosure of Editors' Financial Relationships

Published Online:1 Apr 2018https://doi.org/10.1176/appi.ajp.2017.17504386

The American Journal of Psychiatry requires its editors to disclose any financial relationships with commercial interests, including consulting with pharmaceutical companies or receiving honoraria from them. These relationships were as follows:

Robert Freedman, M.D., reports no financial relationships with commercial interests.

David A. Lewis, M.D., currently receives investigator-initiated research support from Pfizer and serves as a consultant to Merck.

Robert Michels, M.D., reports no financial relationships with commercial interests.

Daniel S. Pine, M.D., reports no financial relationships with commercial interests.

A. John Rush, M.D., consulting fees from Akili, Brain Resource Inc., Compass Inc., CurbstoneConsultant LLC, Eli Lilly, Emmes Corp., John Peter Smith Healthcare, Liva-Nova, Mind Line, Sunovion, Takeda USA, Taj Medical, UT Southwestern Medical Center at Dallas; speaking fees from Liva-Nova and Sing-Health; and royalties from Guilford Press and UT Southwestern, Dallas (for the Inventory of Depressive symptoms and its derivatives such as the QIDS-C). He is a named co-inventor on two patents: U.S. Patent No. 7,795,033 (Methods to Predict the Outcome of Treatment with Antidepressant Medication; Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS) and U.S. Patent No. 7,906,283 (Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication; Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S).

Susan K. Schultz, M.D., has received research support from the Alzheimer’s Disease Cooperative Study for projects conducted in partnership with Toyama Chemical Company and in partnership with Eli Lilly and Company.

Carol A. Tamminga, M.D., has received research support from Sunovion and travel funds from Autiphony Therapeutics and has served as a consultant for Astellas, Eli Lilly, Kaye Scholer LLC for Pfizer, and Lundbeck.